EH
CN
Home
Haisco
Group Profile
Subsidiary Profile
Production Base
Production Equipment
Production Capacity
Products
corporate Culture
Enterprise Philosophy
Employee Benefits
Employees
Enterprise Magazine
Contact Us
Product
Narcotic Analgesics
Endocrine System Drugs
Enteral Parenteral Nutrition Drugs
Neuropsychiatric Drugs
Cardiovascular Drugs
Tumor Related Drugs
Drugs For Digestive Liver Disease
Other
Innovative R&D
Innovative R&D
Our Science
Clinical Trial
Platform
Partnership
Investor
Stock Information
Investor Hotline
Contact Us
EH
CN
Haisco
Group Profile
Subsidiary Profile
Production Base
Production Equipment
Production Capacity
Products
corporate Culture
Enterprise Philosophy
Employee Benefits
Employees
Enterprise Magazine
Contact Us
Product
Narcotic Analgesics
Endocrine System Drugs
Enteral Parenteral Nutrition Drugs
Neuropsychiatric Drugs
Cardiovascular Drugs
Tumor Related Drugs
Drugs For Digestive Liver Disease
Other
Innovative R&D
Innovative R&D
Our Science
Clinical Trial
Platform
Partnership
Investor
Stock Information
Investor Hotline
Home
>
Haisco
>
Historical evolution
>
2020
07月17日
2022-01-07 15:27:52
为推进公司产品在海外的临床研究,公司控股子公司 HAISCO PHARMACEUTICAL HOLDINGS GROUP LIMITED 设立全资子公司 Haisco Pharmaceutical PTE. LTD.。
Returns